TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33952735

Group type: EXPERIMENTAL
Intervention: Consumption of vegetable oil of Vitis vinifera L. or Persea americana L. (10 mL)
Number of subjects: 2
Study: 32474978

Group type: EXPERIMENTAL
Intervention: Family intervention support
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Accessing additional support from family intervention
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Communicating openly with the individual
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Engaging with services for the individual
Number of subjects: 10
Study: 34764637

Group type: EXPERIMENTAL
Intervention: Remimazolam (a bolus of 0.1 mg kg‐1, iv)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lidocaine (a bolus of 0.5 mg kg‐1, iv)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal Saline (0.9% normal saline, iv)
Number of subjects: 0
Study: 32584935

Group type: EXPERIMENTAL
Intervention: 300 mg of UDCA
Number of subjects: 521

Group type: EXPERIMENTAL
Intervention: 600 mg of UDCA
Number of subjects: 521

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 521
Study: 35817022

Group type: EXPERIMENTAL
Intervention: sotagliflozin 400 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: empagliflozin 25 mg
Number of subjects: 40
Study: 34878992

Group type: EXPERIMENTAL
Intervention: Self-monitoring group (study 1)
Number of subjects: 297

Group type: COMPARATOR
Intervention: Social norm information (study 1)
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Self-monitoring group (study 2)
Number of subjects: 297

Group type: COMPARATOR
Intervention: Social norm information (study 2)
Number of subjects: 297
Study: 616117540

Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 598

Group type: COMPARATOR
Intervention: Bevacizumab
Number of subjects: 598

Group type: EXPERIMENTAL
Intervention: Presence of retinal angiomatous proliferation (RAP) lesions
Number of subjects: 598

Group type: EXPERIMENTAL
Intervention: Presence of subretinal fluid
Number of subjects: 598

Group type: EXPERIMENTAL
Intervention: Presence of sub-RPE fluid
Number of subjects: 598

Group type: EXPERIMENTAL
Intervention: Foveal sub-RPE fluid
Number of subjects: 598

Group type: EXPERIMENTAL
Intervention: Extrafoveal fluid
Number of subjects: 598
Study: 34350546

Group type: EXPERIMENTAL
Intervention: TA-ER 32 mg
Number of subjects: 25

Group type: COMPARATOR
Intervention: TAcs 40 mg
Number of subjects: 25
Study: 36315249

Group type: EXPERIMENTAL
Intervention: Innominate artery cannulation
Number of subjects: 111

Group type: COMPARATOR
Intervention: Axillary artery cannulation
Number of subjects: 111
Study: 33957783

Group type: EXPERIMENTAL
Intervention: Manual acupuncture plus standard care (ASC)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sham acupuncture plus standard care (SSC)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 120
Study: 32604218

Group type: EXPERIMENTAL
Intervention: Endurance exercise training (ET) for 16 weeks, ≤ 60 min of moderate-intensity ET 3 times/week
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Endurance exercise training (ET)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Attention control (CON)
Number of subjects: 116
Study: 35034431

Group type: EXPERIMENTAL
Intervention: Gadolinium injection at 1 times dose (Group A)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Gadolinium injection at 1.5 times dose (Group B)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Gadolinium injection at 2 times dose (Group C)
Number of subjects: 90
Study: 33757719

Group type: EXPERIMENTAL
Intervention: Dry cupping therapy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sham cupping therapy
Number of subjects: 90
Study: 32811738

Group type: EXPERIMENTAL
Intervention: 1 min stair climbing and descending bouts (SCD)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 3 min stair climbing and descending bouts (SCD)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 10 min stair climbing and descending bouts (SCD)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 0 min (seated control)
Number of subjects: 30
Study: 34878637

Group type: EXPERIMENTAL
Intervention: Moderate-intensity continuous training plus high-intensity interval training (ExComb)
Number of subjects: 945

Group type: EXPERIMENTAL
Intervention: ExComb (Men)
Number of subjects: 945

Group type: EXPERIMENTAL
Intervention: Each 1 metabolic equivalent of task increase in peak oxygen uptake
Number of subjects: 945

Group type: EXPERIMENTAL
Intervention: Participants whose peak oxygen uptake decreased
Number of subjects: 945

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 945
Study: 35115337

Group type: EXPERIMENTAL
Intervention: UC+TCZ (tocilizumab 8 mg·kg‐1)
Number of subjects: 188

Group type: COMPARATOR
Intervention: UC (usual care)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: UC+SARI (sarilumab 200 mg)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: UC+TCZ (tocilizumab)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: UC+SARI (sarilumab)
Number of subjects: 188
Study: 33472211

Group type: EXPERIMENTAL
Intervention: Oxytocin challenge test (OCT) - infusion of oxytocin 5 IU/500 mL Ringer lactate at a rate of 12 mL/h, doubling every 10 min until inducing 5 uterine contractions per 15-min interval.
Number of subjects: 1450

Group type: COMPARATOR
Intervention: Placebo (not specified in detail)
Number of subjects: 1450
Study: 36275949

Group type: EXPERIMENTAL
Intervention: Microlearning after class
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no microlearning after class)
Number of subjects: 0
Study: 35006022

Group type: EXPERIMENTAL
Intervention: Forgiveness bibliotherapy (experimental group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-contact control group
Number of subjects: 0
Study: 33400910

Group type: EXPERIMENTAL
Intervention: Optimally treated CHD patients
Number of subjects: 13153

Group type: EXPERIMENTAL
Intervention: NT-proBNP levels
Number of subjects: 13153

Group type: EXPERIMENTAL
Intervention: Age and BMI
Number of subjects: 13153

Group type: EXPERIMENTAL
Intervention: Male sex and low physical activity
Number of subjects: 13153
Study: 34837528

Group type: EXPERIMENTAL
Intervention: Peloid therapy (5 days a week for 3 weeks at 45 °C for 30 min each day)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Peloid therapy
Number of subjects: 156

Group type: COMPARATOR
Intervention: Control (home exercise program and cold application)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Kinesio taping (6 treatment days 2 times a week)
Number of subjects: 156
Study: 32663119

Group type: EXPERIMENTAL
Intervention: 30 Gy in 5 once-weekly fractions of 6.0 Gy
Number of subjects: 915

Group type: EXPERIMENTAL
Intervention: 28.5 Gy in 5 once-weekly fractions of 5.7 Gy
Number of subjects: 915

Group type: COMPARATOR
Intervention: 50 Gy in 25 fractions (5 weeks)
Number of subjects: 915
Study: 34849744

Group type: EXPERIMENTAL
Intervention: ICD patients with pathological Q waves
Number of subjects: 1477

Group type: EXPERIMENTAL
Intervention: ICD patients with QTc interval increase
Number of subjects: 1477

Group type: COMPARATOR
Intervention: Control patients (700 patients)
Number of subjects: 1477
Study: 32156142

Group type: EXPERIMENTAL
Intervention: In-bed cycling combined with passive joint activities of upper limbs
Number of subjects: 107

Group type: COMPARATOR
Intervention: Routine intensive care (Control)
Number of subjects: 107
Study: 35552068

Group type: EXPERIMENTAL
Intervention: Ischemia-Reperfusion (IR) injury
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control arm (no IR injury)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Comparison of change in sweat sodium concentration
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Local sweat rate during ischemia
Number of subjects: 15
Study: 34052847

Group type: EXPERIMENTAL
Intervention: Response-adaptive SMART (RA-SMART) design
Number of subjects: 0

Group type: COMPARATOR
Intervention: SMART design
Number of subjects: 0
Study: 32049675

Group type: EXPERIMENTAL
Intervention: ALPPS
Number of subjects: 100

Group type: COMPARATOR
Intervention: TSH
Number of subjects: 100
Study: 32653055

Group type: EXPERIMENTAL
Intervention: Ruxolitinib cream 1.5% twice daily
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Ruxolitinib cream 1.5% once daily
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Ruxolitinib cream 0.5% once daily
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Ruxolitinib cream 0.15% once daily
Number of subjects: 157

Group type: COMPARATOR
Intervention: Vehicle (control group)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Ruxolitinib cream (all doses)
Number of subjects: 157
Study: 36107535

Group type: EXPERIMENTAL
Intervention: Liriope platyphylla extract (LP) 1000 mg per day for 4 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (dextrin) 1000 mg per day for 4 weeks
Number of subjects: 22
Study: 34585252

Group type: EXPERIMENTAL
Intervention: 15 mg intrathecal methotrexate
Number of subjects: 53

Group type: COMPARATOR
Intervention: 10 mg intrathecal methotrexate
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Targeted therapy
Number of subjects: 53
Study: 36518417

Group type: EXPERIMENTAL
Intervention: Diabetes group
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 85
Study: 34059720

Group type: EXPERIMENTAL
Intervention: Isoenergic protein-rich formula diet (P-FD)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Fat-rich formula diet (F-FD)
Number of subjects: 130
Study: 35802191

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate air‐powder abrasion (test-group 1)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate air‐powder abrasion supplemented by amino acid buffered hypochlorite solution (test-group 2)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Comparison between test-group 1 and test-group 2
Number of subjects: 20
Study: 32928049

Group type: EXPERIMENTAL
Intervention: Early tracheostomy tube change (day 4)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Late tracheostomy tube change (day 7)
Number of subjects: 16
Study: 32967877

Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m²) followed by intravenous immunoglobulin (IVIg) with an initial dose of 2 g/kg and 1.5 g/kg injections once a month for 5 months (maximum dose: 100 g)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rituximab alone (375 mg/m²)
Number of subjects: 0
Study: 34044830

Group type: COMPARATOR
Intervention: Butorphanol 2.5 μg/kg
Number of subjects: 480

Group type: COMPARATOR
Intervention: Butorphanol 5 μg/kg
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Butorphanol 7.5 μg/kg
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Butorphanol 10 μg/kg
Number of subjects: 480
Study: 32247598

Group type: EXPERIMENTAL
Intervention: Laparoscopic-guided rectus sheath block (LG RSB)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Transincisional rectus sheath block (TI RSB)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both LG and TI RSB
Number of subjects: 48
Study: 34260562

Group type: EXPERIMENTAL
Intervention: Microlaser peeling mode (MM group) with depth of 60μm and a repetition rate of 20%
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Fractional ablative mode (FM group) with depth of 300μm and a fractional density of 8%
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combined mode (CM group) with fractional depth of 200μm, density of 8%, and peeling depth of 30μm, repetition rate of 20%
Number of subjects: 90
Study: 32319358

Group type: EXPERIMENTAL
Intervention: Mediterranean Diet (MeD)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (Iranian traditional diet)
Number of subjects: 80
Study: 34070958

Group type: EXPERIMENTAL
Intervention: AI-driven DDSS (differential diagnosis list)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no AI differential diagnosis list)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: AI-driven DDSS
Number of subjects: 22
Study: 32071329

Group type: EXPERIMENTAL
Intervention: Triple-faceted intervention (mailing reminders, health education, benchmarking PCP procedures)
Number of subjects: 2236

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 2236
Study: 34171526

Group type: EXPERIMENTAL
Intervention: Extended scoring model for IANI risk assessment based on CBCT features
Number of subjects: 1573

Group type: COMPARATOR
Intervention: Baseline model for IANI risk assessment
Number of subjects: 1573
Study: 34125923

Group type: EXPERIMENTAL
Intervention: Telerehabilitation (8 weeks, 5 days/week, daily cost of 74 PLN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (costs from extra in-patient and out-patient rehabilitation)
Number of subjects: 0
Study: 32307655

Group type: EXPERIMENTAL
Intervention: Higher BMI (genetically induced 1 unit increase)
Number of subjects: 101447

Group type: EXPERIMENTAL
Intervention: Low and high BMI (observational)
Number of subjects: 101447

Group type: EXPERIMENTAL
Intervention: High BMI (observational)
Number of subjects: 101447

Group type: EXPERIMENTAL
Intervention: High BMI (causal association)
Number of subjects: 101447
Study: 35144608

Group type: EXPERIMENTAL
Intervention: Simulation-based education program
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 34655945

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 35876325

Group type: EXPERIMENTAL
Intervention: Nutritionist-delivered coaching telephone calls over 8 weeks with an accompanying workbook on lifestyle changes
Number of subjects: 373

Group type: COMPARATOR
Intervention: Workbook in eight mailings without nutritionist coaching calls
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Post-pandemic onset group
Number of subjects: 373
Study: 34221630

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 106

Group type: COMPARATOR
Intervention: Desflurane
Number of subjects: 106
Study: 34719055

Group type: EXPERIMENTAL
Intervention: Manual (traditional) evaluation
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Computer-assisted evaluation
Number of subjects: 44
Study: 32876479

Group type: EXPERIMENTAL
Intervention: Standard risk information about diabetes or CRC
Number of subjects: 1276

Group type: EXPERIMENTAL
Intervention: Low literacy risk information about diabetes or CRC
Number of subjects: 1276

Group type: EXPERIMENTAL
Intervention: Self-affirmation intervention
Number of subjects: 1276

Group type: COMPARATOR
Intervention: No self-affirmation intervention
Number of subjects: 1276
Study: 35209847

Group type: EXPERIMENTAL
Intervention: Fentanyl 8.3 μg/kg
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Oxycodone 0.5 mg/kg
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Butorphanol 0.16 mg/kg
Number of subjects: 135
Study: 33452038

Group type: EXPERIMENTAL
Intervention: 5∗ GRIP‐rated slip‐resistant footwear
Number of subjects: 4553

Group type: COMPARATOR
Intervention: usual footwear (control group)
Number of subjects: 4553
Study: 34465495

Group type: EXPERIMENTAL
Intervention: DAS-pass strategy (informational leaflet, patient held record, guidance by a specialized rheumatology nurse)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 199
Study: 32746904

Group type: EXPERIMENTAL
Intervention: Fermented soy supplementation (Lactobacillus delbrueckii fermented with soy flour, 3 sachets of 1g each)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Fermented soy supplementation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 50
Study: 33893572

Group type: EXPERIMENTAL
Intervention: Bystander-focused violence prevention program (Bringing in the Bystander-High School Curriculum)
Number of subjects: 2403
Study: 35574910

Group type: EXPERIMENTAL
Intervention: Home-based exercise program with augmented reality system (smart-rehab group)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Written and pictorial home-based exercise program (control group)
Number of subjects: 68
Study: 34446504

Group type: EXPERIMENTAL
Intervention: 50 mg spironolactone daily, increasing to 100 mg until week 24
Number of subjects: 398

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 398
Study: 36217366

Group type: EXPERIMENTAL
Intervention: 5-session Step-by-Step program with minimal guidance by trained peer-helpers
Number of subjects: 334

Group type: COMPARATOR
Intervention: Enhanced care as usual (psychoeducational information on depression and anxiety and referrals to local community services)
Number of subjects: 334
Study: 32454209

Group type: EXPERIMENTAL
Intervention: 10 mg/70 kg psilocybin
Number of subjects: 15
Study: 34241706

Group type: EXPERIMENTAL
Intervention: High adherence to integrative care (≥4 IO sessions/6 weeks)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Moderate and low adherence to integrative care (2-3 sessions or <2 sessions)
Number of subjects: 225
Study: 32470981

Group type: EXPERIMENTAL
Intervention: Low-Carbohydrate diet (20% carbohydrate, 60% fat, 20% protein)
Number of subjects: 164

Group type: COMPARATOR
Intervention: High-Carbohydrate diet (60% carbohydrate, 20% fat, 20% protein)
Number of subjects: 164
Study: 36342289

Group type: EXPERIMENTAL
Intervention: Beetroot juice (BJ) 12 ml twice daily
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Beetroot juice (BJ)
Number of subjects: 52
Study: 34425632

Group type: EXPERIMENTAL
Intervention: Shrinkage estimator proposed in the study
Number of subjects: 23551

Group type: COMPARATOR
Intervention: Estimates just significant at the 5% level
Number of subjects: 23551

Group type: EXPERIMENTAL
Intervention: Achieved power
Number of subjects: 23551
Study: 32222267

Group type: EXPERIMENTAL
Intervention: Fascia iliaca compartment block
Number of subjects: 122
Study: 33507722

Group type: EXPERIMENTAL
Intervention: Daily GnRH agonist for luteal phase support (0.2 mg subcutaneous injection bid) following GnRH agonist trigger
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standard strategy (hCG trigger [10000 IU] and progesterone bid [400 mg/BD] for LPS)
Number of subjects: 44
Study: 32966811

Group type: EXPERIMENTAL
Intervention: Surufatinib (300 mg per day)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Surufatinib
Number of subjects: 198
Study: 35760339

Group type: EXPERIMENTAL
Intervention: Y‐BTI + ATM
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Y‐BTI alone
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: ATM alone
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 100
Study: 34450042

Group type: EXPERIMENTAL
Intervention: Hypothermia treatment for moderate or severe neonatal encephalopathy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study: 34619073

Group type: EXPERIMENTAL
Intervention: Treatment rationale for iCBT
Number of subjects: 662

Group type: COMPARATOR
Intervention: No treatment rationale for iCBT
Number of subjects: 662
Study: 32473974

Group type: EXPERIMENTAL
Intervention: Bimekizumab 64 mg
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Bimekizumab 160 mg
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Bimekizumab 320 mg
Number of subjects: 217

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 217
Study: 37294220

Group type: EXPERIMENTAL
Intervention: Bilateral asymmetrical limb proprioceptive neuromuscular facilitation (PNF) exercises
Number of subjects: 150

Group type: COMPARATOR
Intervention: Swiss ball exercises
Number of subjects: 150
Study: 32047968

Group type: EXPERIMENTAL
Intervention: Permanent suture
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Absorbable suture
Number of subjects: 44
Study: 35619097

Group type: EXPERIMENTAL
Intervention: Multimodal feedback, optional detail, and reduced cognitive load
Number of subjects: 638

Group type: EXPERIMENTAL
Intervention: Multimodal feedback, specific actions, patient voice, and reduced cognitive load
Number of subjects: 638

Group type: COMPARATOR
Intervention: None of the six feedback modifications
Number of subjects: 638

Group type: EXPERIMENTAL
Intervention: Combination of feedback modifications
Number of subjects: 638
Study: 34129601

Group type: EXPERIMENTAL
Intervention: Pyronaridine-artesunate, fixed-dose, once daily for 3 days, dosed by body weight, using tablet formulation for adults/adolescents and pediatric granule formulation for children/infants under 20 kg.
Number of subjects: 7154

Group type: EXPERIMENTAL
Intervention: Pyronaridine-artesunate
Number of subjects: 7154
Study: 33326254

Group type: EXPERIMENTAL
Intervention: GD2/GD3 vaccine plus oral β-glucan
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: β-glucan
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: anti-GD2-IgG1 titer ≥ 150 ng/mL by week 8
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Prior episodes of disease progression and time from last progression to vaccine
Number of subjects: 102
Study: 33081715

Group type: EXPERIMENTAL
Intervention: PAM-based intervention with motivational interviewing
Number of subjects: 0

Group type: COMPARATOR
Intervention: PAM-based intervention (control group)
Number of subjects: 0
Study: 33078664

Group type: EXPERIMENTAL
Intervention: 20% human albumin
Number of subjects: 76

Group type: COMPARATOR
Intervention: Conventional blood prime
Number of subjects: 76
Study: 33351083

Group type: EXPERIMENTAL
Intervention: Manhood 2.0 program (18 hours)
Number of subjects: 866

Group type: COMPARATOR
Intervention: Job-readiness training (control group, 18 hours)
Number of subjects: 866

Group type: EXPERIMENTAL
Intervention: Manhood 2.0 program
Number of subjects: 866
Study: 34610286

Group type: EXPERIMENTAL
Intervention: 20% hypertonic dextrose injection
Number of subjects: 57

Group type: COMPARATOR
Intervention: 5% normal saline (control group)
Number of subjects: 57
Study: 32921992

Group type: EXPERIMENTAL
Intervention: LPV with ARM
Number of subjects: 62

Group type: COMPARATOR
Intervention: LPV only
Number of subjects: 62
Study: 35728160

Group type: EXPERIMENTAL
Intervention: Colposcopy review at the hospital (follow-up (a))
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Follow-up with high-risk human papilloma virus (HrHPV) and smear test in the community (follow-up (b))
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Choice of follow-up options (follow-up (c))
Number of subjects: 200

Group type: COMPARATOR
Intervention: Choice of follow-up (c)
Number of subjects: 200